Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 1997

View Archived Issues

Draxis to promote dermatological drug in Canada

OXiGENE reports favorable preclinical results with Neu-Sensamide and Oxi-104

FDA approval for first-ever home test for use with oral anticoagulant therapy

Creative BioMolecules reports 1996 year-end results

British Biotech announces three-month financial results

Atrix Laboratories announces 1996 year-end results

Major growth in R&D activities in first quarter of 1997 for DiagnoCure

Alteon announces financial results for the fiscal year

Genzyme General's fourth-quarter EPS was $0.29 before acquisition charges

NeXstar Pharmaceuticals announces 1996 and fourth-quarter results

Cypros Pharmaceutical reports second-quarter and six-month results

Genzyme Transgenics and Fresenius to further development of transgenic albumin

BioChem Pharma creates new subsidiary to manage venture capital for genomic research

Positive clinical trial results for CDP-571 in Crohn's disease

Potent, nonselective adenosine agonist from Schering-Plough

Ritonavir approved for pediatric use in U.S.

Repeated IVIg for relapsing-remitting MS

FDA approves Viracept for adult and pediatric use

SIB-1508Y associated with improvement in cognitive deficits in Parkinson's model

Osiris Therapeutics awarded SBIR grant for tendon regeneration research

Astra gains European approval of asthma treatment

Biora establishes subsidiary in Italy

ProCyte's hair transplant wound dressing approved by FDA

Aricept cleared for marketing in U.K.

New therapy for essential tremor recommended for approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...